What is MapLight Therapeutics, Inc. 's change in AP?

MapLight Therapeutics, Inc. (MPLT) reported change in AP of -$111K in Q1 2026.

What does change in AP mean?

Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.

MapLight Therapeutics, Inc. MPLT Change in AP

Change in AP at other companies

Bristol-Myers SquibbBMY

$409M+581%

Johnson & JohnsonJNJ

-$3.92B-84.4%

Neurocrine BiosciencesNBIX

-$14.3M-377%

Acadia PharmaceuticalsACAD

$1.34M-29.4%

AbbVieABBV

-$1.59B-129%

MeiraGTx Holdings plcMGTX

$7.91M+358%

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B—

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's change in AP?: MapLight Therapeutics, Inc. (MPLT) reported change in AP of -$111K in Q1 2026.
What does change in AP mean?: Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.